Register
Login:
Share:
Email Facebook Twitter




Gw Pharmaceuticals Share Chat (GWP)



Share Price: 583.50Bid: 583.00Ask: 583.50Change: 0.00 (0.00%)No Movement on Gw Pharm.
Spread: 0.50Spread as %: 0.09%Open: 590.50High: 592.50Low: 581.50Yesterday’s Close: 583.50


Share Discussion for Gw Pharmaceuticals


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


kingskin
Posts: 1,443
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:596.00
RE: Whats next
Mon 14:08
no probs ;)
 
Freddie2
Posts: 768
Off Topic
Opinion:No Opinion
Price:596.00
RE: Whats next
Mon 14:04
Thanks for that , its been a bit quite lately
kingskin
Posts: 1,443
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:596.00
RE: Whats next
Mon 13:58
earnings and 2nd lot of LGS data, sometime around the 4th.
Freddie2
Posts: 768
Off Topic
Opinion:No Opinion
Price:596.00
Whats next
Mon 13:54
For this share , are there any results due , pretty stagnent at mo usually a good mover !
stevie420
Posts: 424
Off Topic
Opinion:No Opinion
Price:596.00
RE: poporplop/ploporpop ?
Sat 11:11
stevie420
Posts: 424
Off Topic
Opinion:No Opinion
Price:596.00
RE: poporplop/ploporpop ?
Fri 18:30
:)
kingskin
Posts: 1,443
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:594.50
RE: poporplop/ploporpop ?
Fri 16:47
google is saying earnings are 4/8/2016, so its poss we get the LGS data then, but its only an estimate buddy ;)
kingskin
Posts: 1,443
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:595.50
RE: poporplop/ploporpop ?
Fri 16:43
no worries stevie, just had a busy day at work, the info is on page 20 i think..

" In March 2014, we commenced a larger placebo-controlled Phase 2 dose ranging trial of GWP42004. The primary objective of this trial is to compare the change in glycemic control in patients with type-2 diabetes when treated with one of three doses of GWP42004 or placebo as add-on therapy, to metformin with the primary endpoint being change from baseline to the end of treatment in mean glycosylated hemoglobin A1c (HbA1c) level. The safety and tolerability of GWP42004 compared with placebo will also be assessed.

This trial is now completed and a preliminary analysis of the topline data shows that this trial did not meet its primary endpoint. The drug was well tolerated with no serious adverse events. We are undertaking further evaluation of the data to determine whether to pursue further development of GWP42004 within the field of type-2 diabetes. "

http://ir.gwpharm.com/secfiling.cfm?filingID=1144204-16-112989&CIK=1351288
stevie420
Posts: 424
Off Topic
Opinion:No Opinion
Price:596.00
RE: poporplop/ploporpop ?
Fri 15:27
soz i know you must be busy . . . searched here on chat king and GW site and cannot find the copy and paste you did ? if you are able to advise when you have a moment i'd be most appreciative for any guidance that may help ! and . . . . . . abso. no rush :)
kingskin
Posts: 1,443
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:595.50
RE: poporplop/ploporpop ?
Fri 14:11
yeah i think q3 is correct!




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.